Intrauterine growth restriction (IUGR) affects up to 10% of pregnancies in Western societies. IUGR is a strong predictor of reduced short-term neonatal survival and impairs long-term health in children. Placental insufficiency is often associated with IUGR; however, the molecular mechanisms involved in the pathogenesis of placental insufficiency and IUGR are largely unknown. Here, we developed a mouse model of fetal-growth restriction and placental insufficiency that is induced by a midgestational stress challenge. Compared with control animals, pregnant dams subjected to gestational stress exhibited reduced progesterone levels and placental heme oxygenase 1 (Hmox1) expression and increased methylation at distinct regions of the placental Hmox1 promoter. These stress-triggered changes were accompanied by an altered CD8+ T cell response, as evidenced by a reduction of tolerogenic CD8+CD122+ T cells and an increase of cytotoxic CD8+ T cells. Using progesterone receptor– or Hmox1–deficient mice, we identified progesterone as an upstream modulator of placental Hmox1 expression. Supplementation of progesterone or depletion of CD8+ T cells revealed that progesterone suppresses CD8+ T cell cytotoxicity, whereas the generation of CD8+CD122+ T cells is supported by Hmox1 and ameliorates fetal-growth restriction in Hmox1 deficiency. These observations in mice could promote the identification of pregnancies at risk for IUGR and the generation of clinical intervention strategies.

Introduction

Intrauterine growth restriction (IUGR) in humans is associated with poor fetal growth and impaired fetal development. In Western societies, the incidence of IUGR varies to between 3% and 10% of the total population, with an unprecedented increase observed over the last decades (1–4). IUGR not only strongly predicts reduced short-term neonatal survival (5), but is also associated with adverse long-term health outcomes, including increased risk for cardiovascular disease and chronic immune disease (6–8). Maternal factors known to influence fetal development, including age, weight, race, socioeconomic status, nutrition, or smoking, have also been associated with IUGR (3, 9–10). Moreover, high maternal stress perception is increasingly recognized as enhancing the risk for IUGR (11–16). Placental insufficiency is a known contributor to IUGR (17, 18). To date, however, molecular mechanisms leading to IUGR and placental insufficiency are still largely unknown.

Fine-tuned maternal endocrine and immune adaptations interact during pregnancy to create a tolerogenic intrauterine environment that promotes placental development and fetal growth in eutherian mammals (18–21). The placenta mediates the interactions between mother and fetus by providing the fetus with nutrients and oxygen and allowing waste exchange between the fetal and maternal systems (19, 22). This is largely possible through the formation of a complex placental vascular net that closely approximates maternal blood sinuses and fetal capillaries (19, 22). Furthermore, in the mouse placenta, trophoblast cells, such as the parietal giant cells (pGCs), produce a number of paracrine and endocrine hormones, which can stimulate ovarian progesterone production (19, 20).

Progesterone (the progestation hormone) is pivotal for pregnancy success. When pregnancy commences, progesterone stimulates decidualization of endometrial stromal cells and maternal immune adaptation to pregnancy; it subsequently sustains uterine quiescence throughout pregnancy (23–25). There is a significant rise of progesterone during pregnancy, and even subtle deficits can affect the course of pregnancy by increasing the risk of miscarriage (26) or reduced birth weight (27, 28).

In addition to progesterone, emerging evidence suggests that heme oxygenase 1 (HMOX-1), an enzyme that catalyzes the degradation of heme into carbon monoxide, biliverdin, and iron, is also a critical mediator of pregnancy maintenance and placental function (29–32). HMOX-1 is expressed in most tissues, including the placenta in mice and humans (29, 31), and acts as a critical factor for promoting vasculature formation and immune homeo-
stasis by inhibiting overshooting reactions in a number of tissues in the body (31–33). Both progesterone and HMOX-1 can suppress CD4+ effector T cell responses and induce the generation of CD4+ Tregs (34–37), which also promote maternal immune tolerance to the fetus (38, 39). Maternal CD8+ T cell responses can also affect placental function (40–42). Recent studies in mouse models have indicated that the presence of the naturally occurring CD8+ T cell subset CD8+CD122+ T cells is capable of suppressing inflammation in autoimmunity, transplantation, and other inflammatory conditions (43–45). However, to date, the mediators involved in the generation of CD8+CD122+ T cells and their functional role in pregnancy maintenance remain unknown.

The aim of the present study was to develop a mouse model in order to advance our understanding of the underlying molecular mechanisms of fetal-growth restriction. It was our goal to identify an interaction and functional hierarchy between the 2 promoters of pregnancy maintenance, maternal progesterone and placental HMOX-1, as well as their effect on the CD8+ T cell response in the context of fetal growth.

Results

Fetal-growth restriction and features of placental insufficiency are caused by midgestational stress challenge in mice. Maternal stress is known to impair fetal development (13–16). Early during gestation, exposing mouse dams to a sound stress challenge is associated with an increase in the fetal loss rate (25, 46). To develop a mouse model of fetal-growth restriction and placental insufficiency, we exposed pregnant dams to sound stress at midgestation (gestation day [gd12.5]), when placentation is largely completed. We rechallenged the dams with sound stress on gd14.5. Using this intervention, we observed a significant delay in fetal development according to the Thelier stage (TS) criteria measurements on gd16.5 (Figure 1, A–C). Average fetal weight was also significantly decreased in stress-challenged fetuses compared with non-stressed controls (Figure 1D). The midgestational stress challenge did not affect litter size, fetal loss, or gestational length (Figure 1E and Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI68140DS1). Following parturition, a significant decrease in neonatal weight was also observed on postnatal day 2 (Figure 1F).

Initially a significant decrease in placental weight was observed in stress-challenged litters on gd14.5; however, on gd16.5, placental weights returned to values similar to those seen in control mice (Supplemental Figure 1C). The surfaces of 2 placental functional areas, the labyrinth and junctional zone, were evaluated histomorphologically in order to calculate the labyrinth/junctional zone (L/Jz) ratio. The L/Jz ratio has been used as a marker for placental function (47). We observed significant changes of the L/Jz ratio on gd13.5 and gd14.5, indicative of a relative labyrinth reduction in response to stress challenge. Commencing on gd15.5, the L/Jz ratio was then inverted due to a relative increase of the labyrinth (Figure 1, G and D). These histomorphological findings were confirmed by MRI of the placentas taken on gd16.5 (Supplemental Figure 1, D and E, and Supplemental Methods). Since the labyrinth comprises a complex vascular network promoting nutrient and oxygen transfer to the fetus (19, 22), we evaluated fetal vessel density, identified by the presence of CD34+ vessels, in the placental labyrinth. We focused on distal areas of the labyrinth, where blood perfusion is less affected by the high blood flow along the central arterial placental canal or the chorial plate vessels, as identified by MRI (Supplemental Figure 1E). Labyrinth vessel density increased during the progression of pregnancy in control animals, showing a substantial increase from gd15.5 to gd16.5. On gd14.5, a decrease in vessel density was present in stress-challenged animals; this was reversed on gd16.5 (Figure 1, H and I).

Collectively, these data indicate that the prenatal stress challenge at midgestation in mice resulted in fetal-growth restrictions that were associated with markers of placental insufficiency, including reduced vascularization, similar to the clinical signs of IUGR in humans.

Progesterone and placental Hmox1 expression are reduced and CD8+ T cell response is altered in fetal-growth restriction. We observed a significant decrease in serum progesterone levels in stress-challenged dams (Figure 2A). Further evidence of stress-related decreases in progesterone levels was provided through kinetic studies using urine samples (Supplemental Figure 2A and Supplemental Methods). Reduced placental expression of proliferin and placental lactogen II (Prl3b1) suggested reduced placental endocrine activity (20) in response to stress (Supplemental Figure 2, B–D, and Supplemental Methods). An increase in pGC death accounting for these alterations was excluded, as apoptotic pGCs did not differ between groups (Supplemental Figure 2, E and F). We also observed a significant decrease in ovarian expression of 3β-hydroxysteroid dehydrogenase (Hsd3b1), which converts pregnenolone to progesterone, and a reduction of the ovarian steroidogenic acute regulatory protein (Star), which transports cholesterol from the outer to the inner mitochondrial membrane (Supplemental Figure 2, G and H). These findings suggest that progesterone synthesis was impaired in ovaries of stress-challenged mice. As ovarian expression of 20αHSD (Akr1c18) was very low and there were no significant differences between control and stressed animals at midgestation (data not shown), the observed decrease in progesterone levels was not due to changes in progesterone metabolism rates.

A direct link between progesterone availability and fetal growth was confirmed through experiments with progesterone receptor transgenic (Pgr) mice. Upon mating of Pgr−/− females to Pgr−/+ males, which results in implantations of Pgr−/−, Pgr−/+ and Pgr−/+ genotypes following Mendelian distribution (Supplemental Figure 2B), there was a significant reduction of fetal weight in implantations with the Pgr−/+ genotype compared with Pgr−/+ fetuses in the same litter (Figure 2B). Further, these changes in fetal weight were accompanied by reduced placental L/Jz ratios due to a decrease in labyrinth size (Figure 2C).
Stress-challenged females also showed a significant decrease in placental Hmox1 mRNA expression (Figure 2D). HMOX-1 is also expressed on protein levels in the placental labyrinth, pGC, placenta-infiltrating leukocytes, and in decidua and myometrium (Figure 2E and Supplemental Figure 3, A and B). DNA methylation in a CpG island around the transcription start site of the Hmox1 gene was analyzed using pyrosequencing, as altered methylation could account for the downregulation of placental Hmox1 expression. Overall, regardless of stress exposure, we observed low levels of CpG methylation of the Hmox1 promoter region in the placenta. However, the methylation in 2 CpG positions was significantly increased in the placentas of prenatally stressed females (Figure 2F). Interestingly, the first of these CpG positions (−109) is adjacent to the binding site for the transcription factor specificity protein-1 (SP-1) (Supplemental Table 4).
We then sought to confirm the link between reduced placental Hmox1 expression and fetal weight by mating Hmox1+/– females with Hmox1+/+ males. This mating combination resulted in fetuses with Hmox1+/+, Hmox1+/–, and Hmox1–/– genotypes. The Mendelian distribution — as expected from published evidence (31) — is disrupted in this mating combination, as shown through the reduced frequency of implantation sites of the Hmox1–/– genotype (13% instead of an expected 25%). Reduced levels or a complete absence of Hmox1 expression in Hmox1+/– (13% instead of an expected 25%) or Hmox1–/– mice, the labyrinth area was also reduced in Hmox1–/– mice. There was a disproportionate decrease of the junctional zone.

Based on the well-known functions of progesterone and HMOX-1 in modulating immune responses in conjunction with the observed responses to a stress challenge reported here, we assessed the effect of stress challenge on distinct immune cell subsets in uterus-draining lymph nodes. No changes in the proportion of CD4+ T cells and CD4+ Tregs were found (Figure 3, A and B), but there was an overall increase in CD8+ T cell frequencies in response to the stress challenge (Figure 3C). This CD8+ T cell increase was associated with a decrease in the CD8+CD122+ T cell subset (Figure 3, D and E) and a skew toward cytotoxic, CD107α+IFN-γ CD8+ T cells in response to the stress challenge (Figure 3, H and I), albeit at very low frequencies compared with T cells.

**Progestosterone is an upstream modulator of placental Hmox1 expression.** As shown in Figure 2, we observed impaired fetal growth and signs of placental insufficiency in pregnancies with low levels of progesterone and reduced placental expression of Hmox1 in dams exposed to a stress challenge. These findings were strengthened by our observations of fetal-growth restriction in Pgr+−/+ × Pgr+−/+ mating combinations. Therefore, we aimed to test for an interaction and determine the functional hierarchy between these 2 markers. We first assessed placental Hmox1 in Pgr+−/+ females mated to Pgr+−/+ males. This mating combination resulted in fetus-placental Pgr genotypes and placental L/Jz ratio obtained from analyses of Masson-stained placental tissue sections taken on gd16.5. (Figure 2H).}

**Figure 2. Progesterone levels and placental Hmox1 expression are reduced in fetal-growth restriction.** (A) Levels of serum progesterone in control and stress-challenged dams on gd16.5, as analyzed by RIA. (B) Fetal weight and (C) placental L/Jz ratio in gd13.5 placentas resulting from Pgr+−/+ × Pgr+−/+ mating combinations. The fetal/placental Pgr genotypes are provided under the respective bars. (D) Fold change (FC) in Hmox1 mRNA expression quantified by RT-PCR in placental samples from control and stress-challenged pregnancies on gd16.5. (E) Photomicrographs showing detail of the labyrinth and junctional zone areas of representative placental tissue sections upon immunohistochemical detection of HMOX-1 (appears brown). Tissue was counterstained with hematoxylin. Scale bar: 0.1 mm. (F) Pyrosequencing methylation analysis of a CpG island in the Hmox1 promoter region in placenta samples from control and stress-challenged dams on gd16.5 (n ≥ 7). The CpG island locates 110-bp upstream and 172-bp downstream from the transcriptional start site, which is denoted as 1. (G) Fetal weight in offspring arising from Hmox1+−/+ × Hmox1+−/+ mating combinations. The fetal/placental Hmox1 genotypes are provided under the respective bars. (H) L/Jz ratio obtained from analyses of Masson-stained placental tissue sections taken on gd16.5 from Hmox1+−/+ × Hmox1+−/+ mating combinations. The n used in each group and experiment is depicted inside the bars (A–D and G–H). Data are presented as mean ± SEM per respective group. *P ≤ 0.05; **P ≤ 0.01. Analyses were performed using Mann-Whitney U test (A, D, and F) and the Kruskal-Wallis test (B, C, G, and H).
Progestrone failed to restore, we aimed to identify pathways promoting the generation of CD8+CD122+ T cells. A reduction in the proportion of CD8+CD122+ T cells in uterus-draining lymph nodes of Pgr+/– mice on gd13.5 was observed when compared with WT mice (Figure 5A). Similarly, the proportion of CD8+CD122+ T cells was significantly lower in uterus-draining lymph nodes of Hmox1+/– mice compared with WT mice (Figure 5B). Since progesterone levels were similar in Hmox1+/– and Hmox1+/+ mice, these observations suggest that Hmox1, while sustained by progesterone, promotes the generation of CD8+CD122+ T cells.

To strengthen this, we tested the effect of experimental HMOX-1 upregulation by cobalt protoporphyrin (CoPP) administration (48). Here, we focused on nonpregnant mice, since the options to use CoPP during pregnancy are very limited, due to its severe endocrine side effects (49, 50) and possible teratogenicity. Indeed, CoPP injection resulted in a significant increase of CD8+CD122+ T cells in uterus-draining lymph nodes (Figure 5C), confirming the notion that Hmox1 promotes the generation of CD8+CD122+ T cells.

We then assessed the functional role of CD8+CD122+ T cells in fetal growth and placental function by transferring CD8+CD122+ males and observed a significant reduction in Hmox1 expression in Pgr+/– placentas compared with Pgr+/+ placentas (Figure 4A). Furthermore, when stress-challenged dams were administered supplemental progesterone, an upregulation of placental Hmox1 expression, along with an improvement in fetal weight and development, was observed. The placental L/Jz ratio was restored, and the stress-induced skew toward CD8+ T cell cytotoxicity was not seen in stress-challenged dams following the administration of progesterone (Figure 4B). Surprisingly, supplemental progesterone had no impact on the proportion of CD8+CD122+ T cells detected. These findings strongly support an upstream function of progesterone in regulating placental Hmox1 expression and dampening CD8+ T cell cytotoxicity, which does not appear that Hmox1 modulates progesterone levels during murine gestation, as levels of progesterone were similar in WT mice and Hmox1+/– pregnant females (Figure 4C).

Generation of CD8+CD122+ T cells is supported by HMOX-1 and compensates for Hmox1 deficiency–related fetal-growth restriction. Given that we observed a decrease of CD8+CD122+ T cells in response to stress, which administration of supplemental progesterone failed to restore, we aimed to identify pathways promoting the generation of CD8+CD122+ T cells. A reduction in the proportion of CD8+CD122+ T cells in uterus-draining lymph nodes of Pgr+/– mice on gd13.5 was observed when compared with WT mice (Figure 5A). Similarly, the proportion of CD8+CD122+ T cells was significantly lower in uterus-draining lymph nodes of Hmox1+/– mice compared with WT mice (Figure 5B). Since progesterone levels were similar in Hmox1+/– and Hmox1+/+ mice, these observations suggest that Hmox1, while sustained by progesterone, promotes the generation of CD8+CD122+ T cells. To strengthen this, we tested the effect of experimental HMOX-1 upregulation by cobalt protoporphyrin (CoPP) administration (48). Here, we focused on nonpregnant mice, since the options to use CoPP during pregnancy are very limited, due to its severe endocrine side effects (49, 50) and possible teratogenicity. Indeed, CoPP injection resulted in a significant increase of CD8+CD122+ T cells in uterus-draining lymph nodes (Figure 5C), confirming the notion that Hmox1 promotes the generation of CD8+CD122+ T cells.

We then assessed the functional role of CD8+CD122+ T cells in fetal growth and placental function by transferring CD8+CD122+
T cells into Hmox1–/–-mated Hmox1+/– females. Upon CD8+CD122+ T cell transfer, a significant improvement in fetal weight could be observed in fetuses of Hmox1+/– genotypes compared with Hmox1+/– fetuses receiving sham treatment (Figure 5D). This CD8+CD122+ T cell adoptive transfer–induced improvement of fetal weight was accompanied by an increased placental and labyrinth area and a profound increase of the junctional zone (data not shown). This resulted in a decreased L/Jz ratio (Figure 5E). Strikingly, upon transfer of CD8+CD122+ T cells, the Hmox1+/– placentas showed a significant increase in vascularization (Figure 5, F and G). This important role of CD8+ T cells in ensuring fetal growth was further supported by a significant reduction in fetal weight and development and placental L/Jz ratio upon CD8+ T cell depletion, which abrogated the improved fetal weight induced by supplemental progesterone (Figure 5, H–J).

Discussion

Here, we introduce a mouse model of fetal-growth restriction triggered by stress challenge during midgestation. The fetal-growth restriction was accompanied by signs of placental insufficiency, similar to IUGR in humans. In this mouse model, progesterone and placental Hmox1 expression were reduced, and methylation of the Hmox1 promoter was altered. Using this stress model along with Pgr and Hmox1 transgenic mice, we were able to provide evidence that progesterone upregulates placental Hmox1 expression. Moreover, we identified a dichotomous CD8+ T cell response in stress-challenged dams, as shown by an increase in the proportion of cytotoxic CD8+ T cells along with reduced frequencies of CD8+CD122+ T cells coexpressing CD122. We provide evidence that the generation of CD8+CD122+ T cells is promoted by Hmox1 and that adoptive transfer of CD8+CD122+ T cells ameliorated fetal growth and placental vascularization in Hmox1+/– implantations. The conceptual scenario arising from these findings is depicted in Figure 5K.

Placental insufficiency and fetal growth restriction have previously been observed in a number of mouse models. However, these models were largely restricted to the use of genetically engineered mice lacking particular genes, such as endothelial nitric oxide synthase (51, 52) and Hmox1 (31). Compared with these, the model for fetal-growth restriction upon stress challenge used here is of greater clinical relevance, given that the causative mechanisms were mounted endogenously.

One key mechanism leading to fetal-growth restriction that we observed involved changes in progesterone levels. Decreased levels of progesterone were observed in response to the stress challenge, a response that appears to be highly conserved across species (26, 46, 53) despite species-specific differences in progesterone production. Low placenta-dependent stimulation with Prl3b1 and low ovarian expression of the progesterone-synthesizing enzymes Star and Hsd3b1 indicate that the stress-induced decrease of progesterone results from a reduction of progesterone synthesis rather than altered rates of progesterone metabolism via 20αHSD (Akr1c18). However, the ovarian expression of 20αHSD we observed was very low in all groups and may have limited the detection of any potential differences among groups. Moreover, inflammatory markers acting directly at the corpus luteum have been linked to an inhibition of progesterone secre-
tion (54, 55), since the inflammatory stimulus can induce apoptosis in luteal cells and endothelial cells in the corpus luteum. Moreover, macrophages have recently been identified as critically supporting the vascular network required for corpus luteum integrity and production of progesterone during early pregnancy in mice (56). Since we observed an increased inflammatory response upon stress challenge in the present study, disruption of the corpus luteum integrity directly by these inflammatory markers or due to an altered phenotype of macrophages may account for the decreased progesterone production.

In human pregnancy, the ovaries initially produce progesterone until a shift from luteal to placental progesterone production occurs around gestation week 6. The placenta is subsequently the main source of progesterone until term. Insights into how stress challenges affect the production of progesterone or its sites of production are still unknown, as progesterone levels are not routinely assessed in human pregnancies.

We provide evidence that the degree of placental Hmox1 expression is dependent on the availability of progesterone. Indeed, our experiments in Pgr transgenic mice show that placental Hmox1 expression was reduced if progesterone was unavailable due to the reduction or complete absence of the progesterone receptor. Therefore, the low levels of placental Hmox1 expression following the stress challenge, along with placental insufficiency and fetal-growth restriction, may result from low levels of progesterone.

We also reported an epigenetic modulation of the placental Hmox1 promoter that was associated with an increase in methylation in response to stress challenge. Increased methylation levels could account for the decreased placental expression of Hmox1 (57) in response to stress. However, this observation does not yet explain how progesterone can modulate Hmox1 expression. To identify potential pathways, we searched for possible progesterone receptor–binding sites within the promoter region of Hmox1 and showed that the region does not include the known progesterone response element (PRE) or the estrogen and glucocorticoid response elements (58–61). This does not exclude the possibility of such response elements within the promoter region of Hmox1, as our search was restricted to the sequences identified to date.
Furthermore, among the transcription factors that control *Hmox1* promoter, SP-1 can interact with the progesterone receptor in several tissues (62). Of note, one of the differentially methylated CpG positions seen in response to stress challenge is adjacent to the binding site for the SP-1. Hence, additional work is needed to determine whether SP-1 and the progesterone receptor interact in the placenta and whether this potential interaction is affected by the altered methylation of the *Hmox1* promoter.

Functionally, placental HMOX-1 promotes placental vascu-
larization of the labyrinth (63), as shown by decreased micro-
vascular vessel volumes in the labyrinth region of *Hmox1*+/–
placentas compared with placentas from WT mice. This altered
vascularization in *Hmox1*+/– placentas is linked to a decrease of
proangiogenic factors in the placenta (63). These observations
are in line with our findings in stressed mice, in which reduced
placental *Hmox1* expression was associated with a substantially
altered placental vascularization.

In human pregnancies, HMOX-1 is expressed in the placenta and decidua (29, 64–69). Placental HMOX-1 expression has been described as being significantly higher in term human placentas (66), when levels of progesterone as well as estradiol are signifi-
cantly higher than in the first trimester. This supports the notion
that HMOX-1 is modulated by progesterone during human preg-
nancies (64–66). The functional role of placental HMOX-1 in
promoting vascularization during normally progressing pregnan-
cies, or its potential modulation in pregnancy pathologies such
as IUGR, remains unclear, probably due to the use of tissue from
preterm versus full-term pregnancies, low sample numbers, tis-
sue heterogeneity, or different detection methods. However, the
importance of HMOX-1 in human pregnancies may be deduced
from a case report describing how a HMOX-1 deficiency (resulting
from a spontaneous gene mutation in a male child) was associated
with growth restriction (69). Currently, it is not an option to rou-
tinely assess placental HMOX-1 expression during human preg-
nancies. This limitation increases the importance of our finding
that progesterone is an upstream modulator of placental *Hmox1*,
as progesterone levels can be readily monitored during pregnancy
as a potential proxy for placental *Hmox1* expression.

A dichotomous CD8+ T cell response with decreased
CD8+CD122+ T cell frequencies and increased frequencies of cyto-
toxic CD8+ T cells in stress-challenged dams was also reported
here. It has been proposed that progesterone, via the progesterone
receptor and glucocorticoid receptor–dependent pathways (70),
modulates the immune response during pregnancy, including
CD4+ and CD8+ T cell differentiation (25, 46, 71). Interestingly,
compared with WT mice, CD4+ T cells from Pgr−/− mice express
lower levels of TGF-β1 (35) and produce significantly more IFN-γ
upon stimulation (36). This is in line with our findings about
the *CD8* T cell response in stress-challenged mice, where progester-
one supplementation reversed CD8+ T cell cytotoxicity. Together,
these findings suggest that progesterone significantly dampens
CD4+ and CD8+ T cell–mediated inflammation, potentially by
opposing the proinflammatory activity of estrogen (72). Reduced
levels of progesterone, as seen in response to stress challenge, may
affect additional immune cell subsets or decidual markers in mice,
such as in dendritic cells, NK cells, or Galectin-1, which can con-
tribute to an impaired pregnancy outcome (25, 34).

Surprisingly, there was only a weak effect of supplemental
progesterone administration on the proportion of CD8+CD122+ T cells. Interestingly, the proportion of CD8+CD122+ T cells decreased in *Pgr*−/− mice as well as in *Hmox1*+/– mice. In the latter,
progesterone levels were similar to those in *Hmox1*+/– mice. We
therefore propose that the generation of CD8+CD122+ T cells dur-
ing pregnancy is largely triggered by HMOX-1, while progesterone
strongly dampens an inflammatory CD8+ T cell response during
pregnancy. This notion is underscored by the absence of PRE in
the CD122 promoter region. Clearly, it is difficult to tease apart
the differential modulation and generation of the CD8+CD122+ T
cell response during pregnancy, as CD8+CD122+ T cell frequen-
cies remained low upon supplemental progesterone and associat-
ated placental *Hmox1* upregulation in stress-challenged dams. This
observation suggests that *Hmox1*-independent mechanisms, such
as direct effects on maternal thymus (73, 74), low levels of TGF-β
(75), or selective glucocorticoid-induced CD8+ Treg apoptosis in
response to stress, could account for the impaired generation of
this cell subset.

In a number of experimental models in mice, CD8+CD122+ T cells have been shown to be indispensable for sustaining
immune homeostasis, including the induction of tolerance or sup-
pression of autoimmunity (44, 45, 76, 77). Insights arising from
*Cd122−/−* mouse studies support the functional role of this marker
in maintaining immune homeostasis, as *Cd122−/−* mice spontane-
ously develop severe hyperimmunity (44, 45, 78, 79). Moreover,
CD8+CD122+ Tregs can maintain homeostasis of CD8+ T cells by
controlling CD8+ T cell activation in vivo and in vitro, mirrored by
dampened IFN-γ production and suppression of CD8+CD122+ T
cell proliferation (45, 78). In addition, CD8+ T cells with regula-
tory functions have been shown to suppress activated CD4+ T cells
(44). The data arising from our experiments of adoptive transfer
of CD8+CD122+ T cells into pregnant *Hmox1*+/− female mice con-
firm the strong regulatory function of these cells during preg-
nancy, which includes the promotion of placental vascu-
larization and fetal development at midgestation in the absence of placental *Hmox1* expression. Critically, no significant effect of CD8+CD122+ T cell transfer was detectable in WT or *Hmox1*+/− implan-
tations (data not shown), which was expected, as the fetal weight reduc-
tion in *Hmox1*+/− implantations was not very profound, thereby lim-
iting the magnitude of reversing effects.

CD8+ cell depletion experiments in stressed mice abrogated
the effect of progesterone supplementation on placental function
and fetal development. Since CD8+ T cell cytotoxicity in these
mice is low, these findings underscore the protective function of
CD8+CD122+ T cells during gestation, as depletion of CD8+ cells
and, hence, absence of CD8+CD122+ T cells accounted for the fail-
ure to successfully support fetal growth.

Strikingly, the generation of CD8+ Tregs has been shown in
HMOX-1+ tumors (80). Here, HMOX-1–specific CD8+ Tregs
exerted immune-suppressive rather than antitumor functions,
suggesting that HMOX-1 may contribute to the development of a
tolerogenic environment and may enable the tumor cells to evade
rejection by the host’s immune system (80). It has been suggested
that these HMOX-1–specific CD8+ Tregs exert a more profound
suppressive activity compared with CD4+ Tregs. In the context
of transplants, HMOX-1–induced modulation of CD8+ T cells has
also been reported, which reduces rejection of organ transplants (81, 82). In the present study, we showed that the generation of CD8+CD122+ T cells with regulatory function was dependent on Hmox1 expression in mice. So far, we were not able to determine whether these CD8+CD122+ T cells are specific for HMOX-1 antigens due to the unavailability of dextramers that are required for detection in mice. Elimination of this technical limitation in the near future will enable elucidation of T cell specificity.

In the current investigation, CoPP-induced HMOX-1 upregulation in vivo resulted in a marked increase of CD8+CD122+ T cells in nonpregnant female mice. These results provide evidence for the role of HMOX-1 in CD8+CD122+ T cell generation. Pharmacological HMOX-1 replacement in our model of stress challenge during midgestation could have provided confirmation that HMOX-1 was the primary pathway affected by stress-induced progesterone deficiency. However, HMOX-1 replacement therapies, such as adrenoviral gene transfer or the application of CoPP, exert effects that may adversely affect pregnancy maintenance by altering the hypothalamic-pituitary release of hormones (49, 50), suppressing appetite (83), and altering insulin sensitivity in tissues (50). Moreover, the possible teratogenic effects of CoPP have yet to be determined.

Our observation that adoptive transfer of CD8+CD122+ T cells overcame fetal-growth restriction in Hmox1+/- implantations suggests a degree of redundancy with regard to the requirement of placental Hmox1 expression for fetal development. Furthermore, while HMOX-1 promotes CD8+CD122+ T cell generation, it does not appear to be necessary for their function during pregnancy, as adaptively transferred CD8+CD122+ T cells increased vascularization in Hmox1+/- placentas.

The results of the present study have potential clinical implications. The detection of low levels of progesterone or an imbalance between cytotoxic and CD8+ Treg subsets prior to the onset of IUGR in human pregnancies could allow the early identification of pregnancies at risk for IUGR. Once these pregnancies are identified, therapeutic interventions aiming to prevent or ameliorate IUGR can be envisioned, such as progesterone supplementation to induce placental HMOX-1 upregulation. To date, progesterone supplementation has been shown to be effective in preventing miscarriage (84) and preterm labor due to a short cervix (85); however, no information is available from placebo-controlled studies on progesterone deficiency. However, HMOX-1 replacement therapy for the role of HMOX-1 in CD8+CD122+ T cell generation, it does not appear to be necessary for their function during pregnancy, as adaptively transferred CD8+CD122+ T cells increased vascularization in Hmox1+/- placentas.

The results of the present study have potential clinical implications. The detection of low levels of progesterone or an imbalance between cytotoxic and CD8+ Treg subsets prior to the onset of IUGR in human pregnancies could allow the early identification of pregnancies at risk for IUGR. Once these pregnancies are identified, therapeutic interventions aiming to prevent or ameliorate IUGR can be envisioned, such as progesterone supplementation to induce placental HMOX-1 upregulation. To date, progesterone supplementation has been shown to be effective in preventing miscarriage (84) and preterm labor due to a short cervix (85); however, no information is available from placebo-controlled studies on progesterone supplementation in IUGR. The therapeutic approach to directly upregulating placental HMOX-1 expression in pregnancies complicated by IUGR by, e.g., CoPP or adrenoviral gene transfer is theoretically also conceivable, although further research is needed to provide insight into possible teratogenic effects. Instead, an upregulation of CD8+ Tregs, which are functionally similar to the CD8+CD122+ T cell subset we identified in mice, could be envisioned in pregnancies affected by IUGR in the future through extracorporeal expansion and adoptive transfer of CD8+ Tregs.

Methods

Animals

Eight-week-old BALB/c female and DBA/2J male mice were purchased from Charles River. BALB/c mice heterozygous for the genetic deletion of HMOX-1 were provided by T.Y. Tsui (University Medical Center Hamburg-Eppendorf). Mice heterozygous for the genetic deletion of Pgr were generated on a C57BL/6/129SvEv background by J. Lydon (Baylor College of Medicine), as previously described (72). The mice were maintained in an animal facility with a 12-hour light/12-hour dark cycle and food and water provided ad libitum.

Experimental design

To investigate the effect of stress during midgestation, DBA/2J-mated BALB/c females were exposed to 24 hours of sound generated by a rodent repellent device (Conrad Electronics) that consisted of a 70-dB tone lasting 1-second long that was repeated 4 times per minute on gd12.5 and gd14.5. Groups of mice were euthanized on gd12.5, gd13.5, gd14.5, gd15.5, and gd16.5. The n of all groups used in the present study is provided in the respective figures. Some of the control and stress-challenged dams were allowed to give birth in order to document gestational length and neonatal weight. To study the role of progesterone and CD8+ cells on stress-induced fetal-growth restriction, some stress-challenged pregnant mice were s.c. injected with the progesterone derivative dihydroxyprogesterone (DHD) (Solvay Pharmaceuticals). Each dam received 1.25 mg of DHD in 0.2 ml of vehicle (20% benzyl benzoate, 80% castor oil) on gd11.5, gd13.5, and gd15.5. Some of the progesterone-supplemented stress-challenged dams were depleted of CD8+ cells (Supplemental Figure 3E) by the i.p. administration of 0.1 mg anti-Lyt 2.1 antibody (BD, catalog 553026) in 0.2 ml PBS on gd10.5, gd11.5, and gd13.5. Control and stressed dams were sham injected employing the corresponding isotype control. On gd16.5, all pregnant BALB/c females were sacrificed.

To study the interaction between progesterone and Hmox1 during pregnancy, Pgr-/- females were mated to Pgr+/- male mice. Tissue collection was carried out on gd13.5. Further, Hmox1+/- females were mated to Hmox1+/- male mice. On gd12.5 a group of dams were adaptively transferred i.v. with 0.3 x 10^6 CD8+CD122- T cells, isolated from lymph nodes and spleen of BALB/c WT mice, in 0.2 ml PBS. Control dams received PBS.

To study the effect of HMOX-1 in vivo induction, virgin 8-week-old BALB/c female mice were administrated 4 times (days 0, 4, 7, and 11) with CoPP (Frontier Scientific Europe) i.p. at 5 mg/kg. CoPP was dissolved in NaOH (0.2 M), adjusted to pH 7.6 with HCl (0.1 M), and diluted in water to obtain a 1 mg/ml stock solution. Control females received PBS. On day 14 after the beginning of CoPP treatment, all animals were euthanized.

At the end point of each experiment, females were anesthetized by CO2 inhalation, blood samples were collected by retroorbital puncture, and mice were subsequently euthanized. The uterus-draining lymph nodes, placentas, and ovaries were collected, and the fetuses were weighed and fixed in Bouin solution. Following Hmox1+/+ and Pgr+/+ mating, fetal tissue samples were collected for genotyping. Depending on the objectives of the experiment, placental tissue was either (a) incubated in RNALater (Invitrogen) and frozen for subsequent real-time PCR (RT-PCR) analysis, (b) embedded in TissueTek (Sakura) media and frozen for subsequent immunohistochemistry, or (c) weighed and fixed in formalin for subsequent paraffin embedding or MRI analysis.

Cell preparations

Uterus-draining lymph nodes and spleens were processed to obtain single-cell suspensions. Briefly, the tissue was mashed through a 40-µm
cell strainer and washed with PBS. Spleen cell suspensions were further depleted of erythrocytes by incubating with rbc lysis buffer (eBioscience). Cells were washed with PBS and resuspended in FACS buffer (0.5% BSA in PBS). Cell viability and concentration were assessed by counting the Trypan blue negative cells in a hemocytometer.

Immune cell phenotype and cytotoxicity were analyzed in lymph node cells by flow cytometry, as described below. For the cell-transfer experiments, lymph node and spleen cells from gd12.5 dams were pooled to isolate CD8\(^{+}\)CD122\(^{+}\) cells.

**Flow cytometry**

Flow-cytometric analyses were carried out following our standard protocol (86). Briefly, 5 \(\times\) \(10^5\) isolated lymphocytes were incubated for 15 minutes in Fe Block solution (0.5% anti-CD16/CD32 antibody, 1% rat normal serum in FACS buffer) to prevent nonspecific binding. After washing, antibodies against specific surface antigens were added at optimal dilutions (Supplemental Table 1), incubated for 30 minutes on ice in the dark, and subsequently washed. For detection of intracellular antigens, cells were fixed and permeabilized using CytoFix/CytoPerm and PermWash buffers (BD Biosciences) according to the manufacturer’s instructions. Cells were then incubated for 30 minutes on ice in the dark with the intracellular antibody at dilutions given in Supplemental Table 1. After washing, cells were resuspended in stabilizing fixative (BD Biosciences). Acquisition was performed using FACS Canto II or LSRFortessa (BD Biosciences) cytometers. Instrument settings were compensated using single-color stained samples, and gating thresholds were established based on the “fluorescence minus one” assessments. Data were analyzed using FlowJo software (TreeStar) to investigate positivity for the markers of interest.

**Cytotoxicity assays**

Intracellular IFN-\(\gamma\) and CD107\(\alpha\) cell surface expression were used as markers for CD8\(^{+}\) cell cytotoxicity, according to published protocols (87). In brief, 10\(^4\) lymph node cells in complete RPMI were stimulated by PMA (10 ng/ml) and ionomycin (1 \(\mu\)g/ml). 2% FITC-labeled CD107\(\alpha\) antibody (BD, catalog 553793) was added directly to the cells and incubated for 1 hour at 37°C in 5% CO\(_2\). Subsequently, 10 \(\mu\)g/ml Brefeldin A and 6 \(\mu\)g/ml monensin (Golgi-Plug and Golgi-Stop, BD Biosciences) were added into the wells and incubated for an additional 5 hours at 37°C in 5% CO\(_2\). Finally, cells were stained for surface-cell markers and intracellular IFN-\(\gamma\) (BD, catalog 554412) following our standard protocol and analyzed by flow cytometry.

**CD8\(^{+}\)CD122\(^{+}\) cell isolation and transfer**

Pregnant WT BALB/c female mice between gd11.5 to gd13.5 were used as donors. Single-cell suspensions were prepared from uterine-draining lymph nodes and spleens. CD8\(^{+}\) cells in cell suspensions were enriched by magnetic cell sorting, using the CD8a\(^{+}\) T Cell Isolation Kit for the untouched isolation of mouse CD8a\(^{+}\) T cells (Miltenyi Biotec, catalog 130-104-075). Upon enrichment, cells were stained and CD8\(^{+}\)CD122\(^{+}\)CD3\(^{-}\)AAD\(^{-}\) cells were isolated employing a FACSAria cell sorter (BD Bioscience). Purity of the cell suspensions was confirmed by subsequent flow cytometry (Supplemental Figure 3F).

**Progesterone analysis in serum**

Serum progesterone concentrations were determined in accordance with the protocol recommended in a commercially available RIA Kit (MP Biomedicals). The sensitivity of the assay was 0.11 ng/ml for progesterone.

**Theiler scoring of fetuses on gd16.5**

Fetal development was evaluated by observation of Bouin-fixed fetuses under a Zeiss Stemi 2000-C stereomicroscope. According to Theiler’s description (88), the main external features used to differentiate the developmental stages at gd16.5 were fusion of eyelids, degree of divergence in the toes of the hind feet, complexion of the skin, and formation of wrinkles.

**PCR determination of Hmox1 and Pgr genotypes**

Genomic DNA was isolated from fetal or adult tissue using the DNaseasy Kit (QIAGEN) according to the manufacturer’s instructions. Hmox1 and Pgr genotypes were determined by PCR employing 2 sets of primers (Supplemental Table 2) in each case. The Hmox1 WT and mutant alleles were identified as 465 bp and 400 bp PCR products respectively. The Pgr WT and mutant alleles generated 856 bp and 580 bp PCR products respectively.

**RT-PCR for Hmox1 mRNA expression and methylation analysis**

**RNA isolation and cDNA synthesis.** Murine placental and ovarian tissue preserved in RNAlater (-20°C) were homogenized using micro packaging vials with ceramic beads (1.4 mm) in the Precellys 24 tissue homogenizer (PeQlab). RNA isolation and subsequent DNA digestion were performed employing the RNeasy Plus Universal Mini Kit (QIAGEN) and the DNA-free Kit (Applied Biosystems). RNA concentration and purity (NanoQuant, Tencan) as well as RNA integrity (Agilent 2100 Bioanalyzer) were assessed. cDNA was synthesized using random primers (Invitrogen). The obtained cDNA was stored at -20°C until further use. Concentration and purity of cDNA were quantified using NanoQuant (Tecan).

Quantification of Hmox1 expression. RT-PCRs were conducted using cDNA as a template. The Applied Biosystems Step One Plus Real-Time PCR Systems and corresponding software were employed in all analysis. A commercially available assay (Applied Biosystems) was used for PCR amplification and detection of Hmox1 (Mm 00516005_m1), whereas we designed the primers and probe to detect hypoxanthine guanine phosphoribosyl transferase (Hprt) (Supplemental Table 3), used as a housekeeping gene. Every sample and target were run in triplicate or quadruplicate. Quantification of the expression of the target gene in relation to the respective housekeeping gene was carried out employing the comparative (\(\Delta\Delta\)Ct) method.

DNA methylation analysis by pyrosequencing. DNA was isolated from RNAlater-preserved tissue using the Nucleospin DNA Kit (Macherey-Nagel). All samples were characterized on a NanoDrop 2000c (ThermoScientific) for purity and concentration of the genomic DNA. Integrity and purity were confirmed on a 0.8% agarose gel. Subsequently, the genomic DNA was treated with bisulfite using the EZ DNA Methylation Kit (Zymo Research) according to the manufacturer’s instructions.

The Hmox1 gene is located on chromosome 8 in mice. Zhao et al. (57) identified 25 CpG dinucleotides around the transcription start site (Supplemental Table 4). Methylation of these CpG positions was analyzed by pyrosequencing on a Pyromark Q24 system (QIAGEN) as described by Freitag et al. (89). The primers were designed using Pyromark Assay Design 2.0 (QIAGEN), using the opposite strand
2. Mortensen LH, Diderichsen F, Davey Smith G, Hmox1+/– tissue sections obtained from
blocked by the incubation of the sections with avidin and biotin-block-
(Fischer) for 30 minutes. Nonspecific binding of avidin and biotin was
incubated with the substrate solution (H2O2/diaminobenzidine in TBS,
tions stained for HMOX-1 were incubated with avidin-biotinylated
the secondary antibody specific against the respective first antibody
After washing, sections were incubated with the solutions containing
night at 4°C with the primary antibody solution (Supplemental Table 7).
Masson-Goldner trichrome staining of placental paraffin sections was as follows: tissue sections were deparaffinized, rinsed in distilled water, and dehydrated twice in ethanol (70%). Masson-Goldner Trichrome Staining Kit (VWR International) was used to visualize the morphologically different areas of placental tissue. Briefly, tissue sections were stepwise stained with Weigert’s iron hematoxylin, azophloxine staining solution, phosphotungstic acid orange G, and light-green SF solution following the manufacturer’s instructions. Finally, the tissue was dehydrated and mounted using Eukitt medium (O. Kindler). Image acquisition was performed using a slide scanner (Mirax Midi, Zeiss). Areas of junctional zone and labyrinth zones were quantified using the program MiraxViewer to calculate a ratio by dividing both values. Furthermore, the level of vascularization was scored (0, low; 3, high) in the labyrinth upon observation of Hmox1+/– placenta tissue sections obtained from Hmox1+/- mating either on uptake adoptive transfer with CD8+CD122+ T cells or PBS injections.

Immunohistochemical detection of HMOX-1 and CD34 in placenta section was performed following established protocols (Supplemental Table 7; refs. 86, 90). Briefly, for CD34 staining, paraffin-embedded tissue sections were deparaffinized, rehydrated, and boiled 2 × 10 minutes in citrate buffer pH 6 for epitope retrieval (Supplemental Table 7). Cryosections were used for HMOX-1 staining. Blocking steps were performed following the special needs for each protocol (Supplemental Table 7). For detecting HMOX-1, endogenous peroxidases were quenched by incubation of the tissue sections in 3% H2O2 in methanol (Fischer) for 30 minutes. Nonspecific binding of avidin and biotin was blocked by the incubation of the sections with avidin and biotin-blocking solutions (Vector). Each blocking step was followed by washes with TBS. Antibody unspecific binding was prevented by a 30-minute incubation with Protein Blocking Agent (Immunotech) or 10% rabbit

Acknowledgments
The authors would like to thank Evelin Hagen, Thomas Andreas, Agnes Wieczorek, Rikst Nyenze Verkaai-Schakel, and Josee Plantinga for excellent technical assistance and Kristin Thiele for her valuable contribution in generating this work. This work was supported by research grants from the German Research Foundation (AR232/19-1; to P.C. Arck), the Werner-Otto Foundation (to M.E. Solano), and the Foundation for Research and Science Hamburg (to P.C. Arck and K. Hecher).

Address correspondence to: María Emilia Solano or Petra Clara Arck, University Medical Center Hamburg-Eppendorf, Laboratory for Experimental Feto-Maternal Medicine, Department of Obstetrics and Fetal Medicine, Martinistr. 52, 20246 Hamburg, Germany. Phone: 49.40.7410.5253; E-mail: e.solano@uke.de (M.E. Solano), p.arck@uke.de (P.C. Arck).
The Journal of Clinical Investigation

Research Article

Downloaded from http://www.jci.org on March 30, 2017. https://doi.org/10.1172/JCI88140

39. Erlebacher A, Zhang D, Parlow AF, Gilmcher LH.


